We thank Adams and Kwee¹ for their interest in our HD16 trial² and their comments. The study in patients with early-stage favorable Hodgkin lymphoma (HL) was designed to clarify whether additional involved-field radiotherapy of 20 Gy can be omitted in patients with a negative fluorodeoxyglucose (FDG) positron emission tomography (PET) scan after 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) without relevant loss of progression-free survival (PFS) and whether a positive PET scan after 2 cycles of ABVD is a risk factor in terms of PFS in these patients.

中文翻译：

---

回复HJA Adams等。

感谢Adams和Kwee ¹对我们的HD16试用版²及其评论的关注。这项针对早期有利霍奇金淋巴瘤（HL）患者的研究旨在阐明，在2个疗程的氟脱氧葡萄糖（FDG）正电子发射断层显像（PET）扫描阴性的患者中，是否可以省略20 Gy的额外累及野放疗在这些患者中，阿霉素，博来霉素，长春碱和达卡巴嗪（ABVD）没有相关的无进展生存期（PFS）损失，并且ABVD 2个周期后PET扫描阳性是否是PFS的危险因素。